Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCYC Bicycle Therapeutics	$8.05 -3.8%	$8.11	$6.10 ▼ $28.67	$555.69M	1.46	389,282 shs	110,850 shs
CDXC ChromaDex		$6.16	$2.31 ▼ $9.18	$611.50M	2.21	813,359 shs	554,788 shs
DNTH Dianthus Therapeutics	$18.24 -0.4%	$19.12	$13.37 ▼ $32.27	$588.05M	1.36	279,662 shs	90,463 shs
MOLN Molecular Partners	$3.85 +0.2%	$3.89	$3.36 ▼ $12.70	$155.28M	1.11	17,700 shs	2,375 shs

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCYC Bicycle Therapeutics	0.00%	-2.11%	+3.33%	-16.13%	-63.77%
CDXC ChromaDex	0.00%	0.00%	0.00%	-0.94%	+163.93%
DNTH Dianthus Therapeutics	0.00%	-2.86%	-7.01%	-16.66%	-29.58%
MOLN Molecular Partners	0.00%	+5.22%	+0.81%	-3.83%	-42.82%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BCYC Bicycle Therapeutics	3.5463 of 5 stars	4.4	1.0	0.0	2.8	4.2	0.6
CDXC ChromaDex	2.5986 of 5 stars	3.5	0.0	4.0	0.6	0.0	1.9
DNTH Dianthus Therapeutics	1.3759 of 5 stars	3.6	0.0	0.0	2.7	0.8	0.0
MOLN Molecular Partners	2.8813 of 5 stars	3.8	5.0	0.0	2.2	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCYC Bicycle Therapeutics	2.70	Moderate Buy	$25.00	210.64% Upside
CDXC ChromaDex	3.00	Buy	$9.03	∞ Upside
DNTH Dianthus Therapeutics	3.13	Buy	$53.00	190.52% Upside
MOLN Molecular Partners	3.50	Strong Buy	$12.00	212.01% Upside

Current Analyst Ratings Breakdown

Latest MOLN, CDXC, DNTH, and BCYC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/13/2025	DNTH Dianthus Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$58.00 ➝ $50.00
5/13/2025	DNTH Dianthus Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $40.00
5/5/2025	BCYC Bicycle Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$15.00 ➝ $17.00
5/2/2025	BCYC Bicycle Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$35.00 ➝ $32.00
5/2/2025	BCYC Bicycle Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$17.00 ➝ $14.00
5/2/2025	BCYC Bicycle Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$26.00 ➝ $22.00
5/2/2025	BCYC Bicycle Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$29.00 ➝ $29.00
5/1/2025	BCYC Bicycle Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$40.00 ➝ $15.00
4/9/2025	BCYC Bicycle Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
3/17/2025	CDXC ChromaDex	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00 ➝ $11.00

(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCYC Bicycle Therapeutics	$25.72M	21.67	N/A	N/A	$12.35 per share	0.65
CDXC ChromaDex	$99.60M	0.00	N/A	N/A	$0.38 per share	0.00
DNTH Dianthus Therapeutics	$6.52M	89.93	N/A	N/A	$11.40 per share	1.60
MOLN Molecular Partners	$2.23M	69.57	N/A	N/A	$5.41 per share	0.71

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCYC Bicycle Therapeutics	-$180.66M	-$3.14	N/A	N/A	N/A	-450.64%	-27.35%	-20.81%	8/5/2025 (Estimated)
CDXC ChromaDex	-$4.94M	$0.10	787.29	0.00	N/A	1.62%	4.85%	2.70%	N/A
DNTH Dianthus Therapeutics	-$43.56M	-$2.88	N/A	N/A	N/A	-1,250.32%	-21.68%	-20.88%	8/6/2025 (Estimated)
MOLN Molecular Partners	-$69.04M	-$1.92	N/A	N/A	N/A	-1,043.01%	-39.31%	-35.46%	8/25/2025 (Estimated)

Latest MOLN, CDXC, DNTH, and BCYC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	MOLN Molecular Partners	-$0.3855	-$0.50	-$0.1145	-$0.50	N/A	N/A
5/12/2025	Q1 2025	DNTH Dianthus Therapeutics	-$0.86	-$0.82	+$0.04	-$0.82	$0.81 million	$1.16 million
5/1/2025	Q1 2025	BCYC Bicycle Therapeutics	-$0.86	-$0.88	-$0.02	-$0.88	$8.67 million	$9.98 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCYC Bicycle Therapeutics	N/A	N/A	N/A	N/A	N/A
CDXC ChromaDex	N/A	N/A	N/A	N/A	N/A
DNTH Dianthus Therapeutics	N/A	N/A	N/A	N/A	N/A
MOLN Molecular Partners	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCYC Bicycle Therapeutics	N/A	17.13	17.13
CDXC ChromaDex	N/A	2.95	2.35
DNTH Dianthus Therapeutics	N/A	18.30	18.30
MOLN Molecular Partners	N/A	14.33	14.33

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCYC Bicycle Therapeutics	86.15%
CDXC ChromaDex	15.41%
DNTH Dianthus Therapeutics	47.53%
MOLN Molecular Partners	26.55%

Insider Ownership

Company	Insider Ownership
BCYC Bicycle Therapeutics	22.90%
CDXC ChromaDex	9.64%
DNTH Dianthus Therapeutics	8.15%
MOLN Molecular Partners	5.93%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCYC Bicycle Therapeutics	240	69.25 million	63.18 million	Optionable
CDXC ChromaDex	120	77.75 million	69.02 million	Optionable
DNTH Dianthus Therapeutics	80	32.16 million	24.70 million	Optionable
MOLN Molecular Partners	180	40.38 million	37.97 million	Not Optionable

MOLN, CDXC, DNTH, and BCYC Headlines

Recent News About These Companies

Molecular Partners Reports Positive Phase 1/2a Data for MP0533 in Relapsed/Refractory AML at EHA Congress

June 12, 2025 | nasdaq.com

Molecular Partners presents positive data from ongoing Phase 1/2a trial of MP0533 in AML at EHA 2025

June 11, 2025 | uk.finance.yahoo.com

Molecular Partners to cut jobs, cash reach now anticipated to extend into 2028

June 10, 2025 | msn.com

Molecular Partners (NASDAQ:MOLN) Shares Up 2.2% - What's Next?

June 10, 2025 | americanbankingnews.com

Molecular Partners (NASDAQ:MOLN) Shares Up 2.2% - Time to Buy?

June 10, 2025 | marketbeat.com

Molecular Partners Announces Planned Operational Efficiencies and Extension of Cash Runway

June 10, 2025 | globenewswire.com

Brokers Offer Predictions for MOLN Q2 Earnings

May 20, 2025 | marketbeat.com

Suvretta Capital Management LLC Has $10.55 Million Stake in Molecular Partners AG (NASDAQ:MOLN)

May 19, 2025 | marketbeat.com

Molecular Partners to Present at Upcoming Investor Conferences

May 19, 2025 | globenewswire.com

Molecular Partners Reports Financial Results and Highlights from Q1 2025

May 16, 2025 | finance.yahoo.com

Molecular Partners presents new data on Radio-DARPin, Switch-DARPin programs

April 26, 2025 | markets.businessinsider.com

Molecular Partners presents new preclinical data on Radio-DARPin and Switch-DARPin programs at AACR 2025

April 25, 2025 | globenewswire.com

Why Molecular Partners AG’s (MOLN) Stock Is Up 5.04%

April 17, 2025 | aaii.com

Molecular Partners Announces all Board Proposals Approved at Annual General Meeting

April 16, 2025 | globenewswire.com

Dendi and Molecular Lab Partners Announce Strategic Partnership to Empower Labs Nationwide

April 15, 2025 | tmcnet.com

Hedge funds owners may take dramatic actions as Molecular Partners AG's (VTX:MOLN) recent 15% drop adds to one-year losses

April 6, 2025 | finance.yahoo.com

Here's Why Molecular Partners AG Sponsored ADR (MOLN) Could be Great Choice for a Bottom Fisher

April 3, 2025 | zacks.com

Why Molecular Partners AG’s (MOLN) Stock Is Up 9.28%

March 27, 2025 | aaii.com

Molecular Partners to hold three poster presentations at AACR 2025

March 25, 2025 | globenewswire.com

Molecular Partners Publishes Invitation to Annual General Meeting 2025

March 25, 2025 | globenewswire.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Molecular Partners (MOLN), United Therapeutics (UTHR) and Universal Health (UHS)

March 17, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MOLN, CDXC, DNTH, and BCYC Company Descriptions

Bicycle Therapeutics NASDAQ:BCYC

$8.05 -0.32 (-3.85%)

Closing price 03:59 PM Eastern

Extended Trading

$8.04 -0.01 (-0.16%)

As of 04:04 PM Eastern

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

ChromaDex NASDAQ:CDXC

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.

Dianthus Therapeutics NASDAQ:DNTH

$18.24 -0.07 (-0.37%)

Closing price 03:58 PM Eastern

Extended Trading

$18.24 0.00 (-0.02%)

As of 04:04 PM Eastern

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Molecular Partners NASDAQ:MOLN

$3.85 +0.01 (+0.16%)

As of 03:47 PM Eastern

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time